NASDAQ: VYGRVoyager Therapeutics Inc Stock
$2.27-0.18 (-7.35%)
Updated Oct 12, 2026
VYGR Price
$2.27
Fair Value Price
N/A
Market Cap
$139.87M
52 Week Low
$2.25
52 Week High
$5.55
P/E
-1.25x
P/B
0.91x
P/S
6.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.46M
Earnings
-$107.73M
Gross Margin
100%
Operating Margin
-312.26%
Profit Margin
-312.6%
Debt to Equity
0.28
Operating Cash Flow
-$121M
Beta
1.31
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VYGR Overview
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VYGR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VYGR
Ranked#332 of 462
Ranked#332 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $7.66 | A | |
| $10.72 | A |
Be the first to know about important VYGR news, forecast changes, insider trades & much more!
VYGR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VYGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VYGR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VYGR is good value based on its book value relative to its share price (0.91x), compared to the US Biotechnology industry average (5.02x)
P/B vs Industry Valuation
VYGR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VYGR due diligence checks available for Premium users.
Valuation
VYGR fair value
Fair Value of VYGR stock based on Discounted Cash Flow (DCF)
Price
$2.27
Fair Value
-$3.05
Undervalued by
174.39%
VYGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VYGR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.25x
Industry
11.37x
Market
48.22x
VYGR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
5.02x
VYGR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VYGR's financial health
Profit margin
Revenue
$3.2M
Net Income
-$24.5M
Profit Margin
-773.2%
VYGR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VYGR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$197.8M
Liabilities
$43.4M
Debt to equity
0.28
VYGR's short-term assets ($125.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYGR's short-term assets ($125.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.8M
Investing
$15.4M
Financing
$2.9M
VYGR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VYGR vs Biotech Stocks
Voyager Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.